Transforming Lung Fibrosis Drug Discovery with the IN MATRICO® Human Lung Fibrosis Platform

Lung extracellular matrix (ECM) is implicated in the pathogenesis and progression of lung fibrosis. Current preclinical lung fibrosis models do not incorporate lung ECM, and therefore lack the defining part of the fibrotic lung disease environment. In this webinar, we describe the paradigm shift in drug discovery from ‘in vitro’ to ‘in matrico’, and present our Human Lung Fibrosis platform for disease modeling and compound testing. Leveraging human fibrotic lung ECM and corresponding clinical data, the platform increases the relevance of cell-based assays and enables lung fibrosis modeling with clinical context to accelerate drug development.